MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications;MDR (multidrug resistance) nell'epatocarcinoma: Implicazioni clinico-terapeutiche

Clinica Terapeutica

Volumn 154, Issue 5, 2003, Pages 325-335

  Petraccia, L ^a   Onori, P ^b   Sferra, R ^b   Lucchetta, M C ^a   Liberati, G ^a   Grassi, Marcello ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

Hepatocarcinoma; MDR

Indexed keywords

ABC TRANSPORTER; ANTISENSE OLIGODEOXYNUCLEOTIDE; BREAST CANCER RESISTANCE PROTEIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RIBOZYME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

EPILEPSY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PHENOTYPE; REVIEW; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; GENETICS; HAMSTER; LIVER TUMOR; MORTALITY; MOUSE; RAT; SURVIVAL; TUMOR RECURRENCE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CRICETINAE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; RATS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 2442689844     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. a ed., Milano, Mc Graw Hill, Vol. 1, Cap.86: 617-618, 1998
2. Walther W, Stein U, Schlag PM: Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes, Int J Cancer 98: 291-296, 2002
3. Sugimoto Y: Gene therapy using anticancer drug-resistance genes, Gan To Kagaku Ryoho, 26(1): 1-9, 1999
4. Zhang JT: The multi-structural feature of the multidrug resistance gene product P-glycoprotein: implications for its mechanism of action (Hypothesis), Molecular Membrane Biology, 18: 145-152, 2001
5. Ejendal KF, Hrycyna CA: Multidrug resistance and cancer: the role of human ABC transporter ABCG2, Curr Protein Pept Sci, 3(5): 503-511, 2002
6. Dalton WS, Scheper RJ: Lung Resistance-Related Protein: Determining Its Role in Multidrug resistance, Journal of the National Cancer Institute, 91(19): 1604-1605, 1999
7. Raidl M, Berger W, Schulte-Hermann R, et al.: Expression of the lung resistance related protein in human and rat hepatocarcinogenesis, Am J Physiol Gastrointest Liver Physiol, 283(5): 1117-1124, 2002
8. Smit J J, Schinkel AH, Mol CA, et al.: Tissue distribution of the human MDR3 P-glycoprotein, Lab. Invest, 71(5): 638-649, 1994
9. Accatino L, Pizarro M, Solis N, et al.: Modulation of hepatic content and biliary excretion of P-glycoprotein in hepatocellular and obstructive cholestasis in the rat, J Hepatol, 25(3): 349-361, 1996
10. Marleen J, De Vree L, Jacquemin E, et al.: Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis, Medical Sciences, 95(1): 282-287, 1998
11. Fojo A T, Ueda K, Slamon DJ, et al.: Expression of a multidrug-resistance gene in human tumors and tissues, Medical Sciences, 84(1): 265-269, 1987
12. Sidorova TA, Nigmatov AG, Kakpakova ES, et al.: Effects of isoprenoid analogues of SDB-ethylenediamine on multidrug resistant tumor cells alone and in combination with chemotherapeutic drugs, Journal of Medical Chemistry, 45(24): 5330-5339, 2002
13. Bates SF, Chen C, Robey R, et al.: Reversal of multidrug resistance: lessons from clinical oncology, Novartis Found Symp, 243: 83-96, 2002
14. Cocker HA, Tiffin N, Pritchard-Jones K, et al.: In Vitro Prevention of the Emergence of the Multidrug Resistance in a Pediatric Rhabdomyosarcoma Cell Line, Clinical Cancer Research, 7(10): 3193-3198, 2001
15. Norman BH, Gruber JM, Hollinshead SP, et al.: Tricyclic Isoxazoles are Novel Inhibitors of the Multidrug Resistance Protein (MRP1), Bioorganic & Medicinal Chemistry Letters, 12(6): 883-886, 2002
16. Burg D, Wielinga P, Zelcer N, et al.: Inhibition of the multidrug resistance 1 (MRP1) by peptidomimetic glutathione-conjugate analogs, Molecular Pharmacology, 62(5): 1160-1166, 2002
17. Peck RA, Hewett J, Harding MW, et al.: Phase I and Pharmacokinetics Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination with Doxorubicin, Journal of Clinical Oncology, 19(12): 3130-3141, 2001
18. Seiden MV, Swenterton KD, Matulonis U, et al.: A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy, Gynecological Oncology, 86(3): 302-310, 2002
19. Kuwano M, Toh S, Uchiumi T, et al.: Multidrug resistance-associated protein subfamily transporters and drug resistance, Anti-Cancer Drug Design, 14: 123-131, 1999
20. Harris MJ, Kuwano M, Webb M, et al.: Identification of the Apical Membrane-Targeting Signal of the Multidrug Resistance-associated Protein 2 (MRP2/cMOAT), The Journal of Biological Chemistry, 276(24): 20876-20881, 2001
21. Wijnholds J: Drug resistance caused by multidrug resistance-associated proteins, Novartis Found Symp, 243: 69-79, 2002
22. Thottassery JV, Zambetti GP, Arimori K, et al.: p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents, Pharmacology, 94(20): 11037-11042, 1997
23. Lee G, Piquette-Miller M: Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells, Cancer Journal of Physiology and Pharmacology, 79: 876-884, 2001
24. Duan Z, Lamendola DE, Person RT, et al.: Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells, Cytokine, 17(5): 234-242, 2002
25. Huesker M, Folmer Y, Schneider M, et al.: Reversal of drug resistance in hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes, Hepatology, 36: 874-884, 2002
26. Sihtil AA, Ktitorova OV, Kakpakova ES, et al.: Differential Effects of the MDR1 (Multidrug Resistance) Gene-Activating Agents on Protein Kinase C: Evidence for Redundancy of the Mechanisms of Acquired MDR in Leukemia Cells, Leukemia and Lymphoma, 40(1-2): 191-195, 2000
27. Masanek U, Stammler G, Volm M: Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides, J Exp Ther Oncol, 2(1): 37-41, 2002
28. Kasimir-Bauer S, Beelem D, Flasshove M, et al.: Impact of the expression of P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long term survival in patients with de novo acute myeloid leukemia, Exp Hemtol, 30(11): 1302-1308, 2002
29. Wartenberg M, Ling FC, Schallenberg M, et al.: Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species, J Biol Chem, 276(20): 17420-17428, 2001
30. Liu X, Song S, Shi C, et al.: Clinical significance of expression of multidrug resistance gene in breast cancer tissue, Zhonghua Yi Xue Za Zhi, 77(7): 488-490, 1997
31. Uematsu T, Hasegawa T, Hiraoka BY, et al.: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas, Int J Cancer, 92(2): 187-194, 2001
32. Obara K, Ghazizadeh M, Shimizu H, et al.: Comparative genomic hybridization study of genetic changes associated with vindesine resistance in esophageal carcinoma, Int J Oncol, 20(2): 255-260, 2002
33. Baldini N, Scotlandi K, Barbanti-Brodano G, et al.: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome, The New England Journal of Medicine, 333(21):1380-1385, 1995
34. Trieb K, Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors, Int J Biochem. Cell Biol, 33(1): 11-17, 2001
35. Dabholkar M, Thornton K, Vionnet J, et al.: Increased mRNA Levels of Xeroderma Pigmentosum Complementation Group B (XPB) and Cokayne's Syndrome Complementation Group B (CSB) without increased mRNA Levels of Multidrug-Resistance Gene (MDR1) or Metallothionein-II (MT-II) in Platinum-Resistant Human Ovarian Cancer Tissues, Biochemical Pharmacology, 60(11): 1611-1619, 2000
36. Ozlap SS, Yalcin OT, Tanir M, et al.: Multidug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies, Eur J Gynaecol Oncol, 23(4): 337-340, 2002
37. Melaine N, Lienard MO, Dorval I, et al.: Multidrug resistance gene and p-glycoprotein in the testis of the rat, mouse, Guinea pig, and human, Biol. Reprod., 67(6): 1699-1707, 2002
38. Tanaka S, Kobayashi I, Oka H, et al.: Drug-resistance gene expression and progression of astrocytic tumors, Brain Tumor Pathology, 18(2): 131-137, 2001
39. Spiegl-Kreinecker S, Buchroithner J, Elbling L, et al.: Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes, J Neurooncol, 57(1): 27-36, 2002
40. Decleves X, Fajac A, Lehmann-Che J, et al.: Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines, Int. J. Cancer, 98(2): 173-180, 2002
41. Flescher E, Rotem R, Kwom P, et al.: Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells, Anticancer Res, 20(6B): 4441-4444, 2000
42. Dombrowski SM, Desai SY, Marroni M, et al.: Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy, Epilepsia, 42 (12): 1501-1506, 2001
43. Newman MJ, Dixon R, Toyonaga B: OC144-093, a novel P glycoprotein inhibitor for the enhancement of antiepileptic therapy, Novartis Found Symp, 243: 213-226, 2002
44. Wang X, Furukawa T, Nitanda T, et al.: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors, Mol Pharmacol, 63(1): 65-72, 2003
45. Delaney WE, Locarini S, Shaw T: Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation, Antiviral Chemistry & Chemotherapy, 12(1): 1-35, 2001
46. Walter H, Low P, Harrer T, et al.: No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual, J Acquir Immune Defic Syndr, 31(2): 137-146, 2002
47. Fellay J, Marzolini C, Meaden ER, et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, The Lancet, 359(9300): 30-36, 2002
48. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view, Journal of Clinical Gastroenterology, 35(5 Suppl. 2): 572-578, 2002
49. El-Serag HB, Mason AC: Rising Incidence of Hepatocellular Carcinoma in the United States, The New England Journal of Medicine, 340(10): 745-750, 1999
50. Dienstag JL, Isselbacher KJ: Tumors of the Liver and Biliary Tract, Harrison's Online, 15th ed., Part 6, Section 1, Ch.91; in www.harrisononline. com.
51. Grassi M, Fontana M, Nocchi S, et al.: L'epatocarcinoma: valutazione epidemiologica e clinica di 90 pazienti, Clin Ter, 151(2): 87-92, 2000
52. Wawrzynivicz-Syczewska M, Leonciuk A, Jurczyk K, et al.: Increased incidence of hepatocellular carcinoma, Pol Merkuriusz Lek, 13(74): 100-102, 2002
53. Bradley G, Sharma R, Rajalakshmi S, et al.: P-glycoprotein expression during tumor progression in the rat liver, Cancer Res, 52(19): 5154-5161, 1992
54. Itsubo M, Ishikawa T, Toda G, et al.: Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma", Cancer, 73(2): 298-303, 1994
55. Soini Y, Virkajarvi N, Raunio H, et al.: Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis, J Clin Pathol, 49(6): 470-473, 1996
56. Takanishi K, Miyazaki M, Ohtsuka M, et al.: Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma, Oncology, 54(3): 231-237, 1997
57. Ng IO, Liu CL, Fan ST, et al.: Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response, Am J Clin Pathol, 113(3): 355-363, 2000
58. Kong XB, Yang ZK, Liang LJ, et al.: Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication, World Journal of Gastroenterology, 6(1): 134-135, 2000
59. Nies AT, König J, Pfannschmidt M, et al.: Expression of the multidrug resistance proteins MRP2 e MRP3 in human hepatocellular carcinoma, Int. J. Cancer, 94(4): 492-499, 2001
60. Hinoshita E, Taguchi K, Inokuchi A, et al.: Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection, Journal of Hepatology, 35(6): 765-773, 2001
61. Bonin S, Pascolo L, Croce LS, et al.: Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol Med, 8(6): 318-325, 2002
62. Ziemann C, Schafer D, Rudell G, et al.: The Cyclooxygenase System Participates in Functional Mdr1b Overexpression in Primary Rat Hepatocite Cultures, Hepatology, 35(3): 579-588, 2002
63. Fantappiè O, Masini E, Sardi I, et al.: The MDR phenotype is associated with the expression of COX-2 and INOS in a human hepatocellular carcinoma cell line, Hepatology, 35: 843-852, 2002
64. 7402 cell line, Cancer Letters, 135: 97-105, 1999
65. 7402, World Journal of Gastroenterology, 8(6): 1029-1034, 2002
66. Yang JY, Luo HY, Lin QY, et al.: Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R, World Journal of Gastroenterology, 8(4): 644-649, 2002
67. Grude P, Conti F, Mennecier D, et al.: MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis, Cancer Letters, 186(1): 107-113, 2002
68. Yeh CN, Cheu MF, Lee WC, et al.: Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis, Journal of Surgical Oncology, 81(4): 195-202, 2002
69. Kato A, Miyazaki M, Ambiru S, et al.: Multidrug Resistance Gene (MDR-1) Expression as a Useful Prognostic Factor in Patient With Human Hepatocellular Carcinoma After Surgical Resection, Journal of Surgical Oncology, 78(2): 110-115, 2001
70. Meaden ER, Hoggard PG, Newton P, et al.: P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals, J Antimicrob Chemother, 50(4): 583-588, 2002
71. Lamba JK, Adachi M, Sun D, et al.: Nonsense mediated decay downregulates conserved alternatively spliced ABCG4 transcripts bearing nonsense codons, Hum Mol Genet, 12(2): 99-109, 2003
72. Vigano C, Julien M, Carrier I, et al.: Structural and functional asymmetry of the nucleotide-binding domains of P-glycoprotein investigated by attenuated total reflection Fourier transform infrared spectroscopy, J Biol Chem, 277(7): 5008-5016, 2002